Literature DB >> 1537718

5-aminolevulinic acid-induced alterations of oxidative metabolism in sedentary and exercise-trained rats.

B Pereira1, R Curi, E Kokubun, E J Bechara.   

Abstract

5-Aminolevulinic acid (ALA), a heme precursor that accumulates in acute intermittent porphyria patients and lead-exposed individuals, has previously been shown to autoxidize with generation of reactive oxygen species and to cause in vitro oxidative damage to rat liver mitochondria. We now demonstrate that chronically ALA-treated rats (40 mg/kg body wt every 2 days for 15 days) exhibit decreased mitochondrial enzymatic activities (superoxide dismutase, citrate synthase) in liver and soleus (type I, red) and gastrocnemius (type IIb, white) muscle fibers. Previous adaptation of rats to endurance exercise, indicated by augmented (cytosolic) CuZn-superoxide dismutase (SOD) and (mitochondrial) Mn-SOD activities in several organs, does not protect the animals against liver and soleus mitochondrial damage promoted by intraperitoneal injections of ALA. This is suggested by loss of citrate synthase and Mn-SOD activities and elevation of serum lactate levels, concomitant to decreased glycogen content in soleus and the red portion of gastrocnemius (type IIa) fibers of both sedentary and swimming-trained ALA-treated rats. In parallel, the type IIb gastrocnemius fibers, which are known to obtain energy mainly by glycolysis, do not undergo these biochemical changes. Consistently, ALA-treated rats under swimming training reach fatigue significantly earlier than the control group. These results indicate that ALA may be an important prooxidant in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537718     DOI: 10.1152/jappl.1992.72.1.226

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  8 in total

1.  Intra-operative acidosis during 5-aminolevulinic acid assisted glioma resection.

Authors:  Ian Anderson; Thomas Naylor; Justin McKinlay; Gnanamurthy Sivakumar
Journal:  BMJ Case Rep       Date:  2015-04-24

Review 2.  Unknown biological effects of L-glucose, ALA, and PUFA.

Authors:  Katsuya Yamada; Daisuke Sato; Takao Nakamura; Hizuru Amano; Yuji Morimoto
Journal:  J Physiol Sci       Date:  2017-05-30       Impact factor: 2.781

3.  Delta-ALA-D inhibitory potential and protective action of Syzygium jambos and Solanum guaraniticum leaf extracts on oxidatively stressed erythrocytes.

Authors:  Gabriela Bonfanti; Karine Santos De Bona; Leidiane de Lucca; Leticia Jantsch; Aline Schirmer Pigatto; Aline A Boligon; Margareth L Athayde; Maria Beatriz Moretto; Thissiane de Lima Gonçalves
Journal:  Redox Rep       Date:  2014-04-12       Impact factor: 4.412

4.  Feasibility of cellular bioenergetics as a biomarker in porphyria patients.

Authors:  Balu Chacko; Matilda Lillian Culp; Joseph Bloomer; John Phillips; Yong-Fang Kuo; Victor Darley-Usmar; Ashwani K Singal
Journal:  Mol Genet Metab Rep       Date:  2019-01-29

5.  Muscle atrophy induced by overexpression of ALAS2 is related to muscle mitochondrial dysfunction.

Authors:  Yahui Peng; Jihong Li; Dixian Luo; Shuai Zhang; Sijia Li; Dayong Wang; Xidi Wang; Zhujun Zhang; Xue Wang; Changhui Sun; Xu Gao; Yang Hui; Rongzhang He
Journal:  Skelet Muscle       Date:  2021-03-30       Impact factor: 4.912

6.  Proteome characteristics of liver tissue from patients with parenteral nutrition-associated liver disease.

Authors:  Gulisudumu Maitiabola; Feng Tian; Haifeng Sun; Li Zhang; Xuejin Gao; Bin Xue; Xinying Wang
Journal:  Nutr Metab (Lond)       Date:  2020-06-03       Impact factor: 4.169

Review 7.  Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution.

Authors:  Miriam Longo; Erika Paolini; Marica Meroni; Paola Dongiovanni
Journal:  Biomedicines       Date:  2022-03-11

8.  Evaluation of Metabolic Changes in Acute Intermittent Porphyria Patients by Targeted Metabolomics.

Authors:  Alex Gomez-Gomez; Paula Aguilera; Klaus Langohr; Gregori Casals; Cristina Pavon; Josep Marcos; Jordi To-Figueras; Oscar J Pozo
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.